

Organized by



Supported by



Endorsed by



Under the patronage of



# ALPE-ADRIA UPDATE ON MOVEMENT DISORDERS TRIESTE - NOVEMBER 9-10-11, 2023

*Directors of the Congress:*

**Michele Tinazzi** (Verona)

**Angelo Antonini** (Padua)

**Paolo Manganotti** (Trieste)




## *Congress Venue:*

**Savoia Excelsior Palace**  
Riva del Mandracchio, 4  
34124 Trieste, Italy

## *Scientific and Organizing Secretariat:*

**Società Italiana Parkinson  
e Disordini del Movimento/LIMPE-DISMOV ETS**  
Viale Somalia, 133  
00199 Rome, Italy  
Tel. +390696046753 - Fax +390698380233  
e-mail: [info@parkinsonlimpedismov.it](mailto:info@parkinsonlimpedismov.it)  
website: [www.parkinsonlimpedismov.it](http://www.parkinsonlimpedismov.it)




**ALPE-ADRIA** was a public Institution founded in Venice in 1978 to promote cooperation between the states of the Eastern Alps and Northern Adriatic sea. The initiative had the finality to develop cooperation and exchanges in Alpe Adria area and increase the processes of integration between European states from Northern Italy to Austria, Slovenia, Croatia, Hungary in science, culture and politics. Despite this Institution has been formally discontinued and this region is now for the most part fully integrated in the Shengen area, the original spirit of cooperation still exists.

The **ALPE-ADRIA Congress on Movement Disorders** wants to revive the old collaborative spirit by involving a group of regional experts with the objective to share new insights and common protocols across the Alpe-Adria region and other Eastern European countries.

The knowledge on pathogenic mechanisms underlying many movement disorders is developing rapidly and will represent an important epidemiological challenge in the next years. The discovery of new pathways in neurodegeneration and the implementation of invasive strategies to treat clinical symptoms offers new and innovative opportunities in the fields of movement disorders.

The Congress addresses different topics including an update on synucleinopathies, advanced therapies in Parkinson, clinical phenotypic characterization of L-Dopa responsive and non-responsive symptoms, advanced neuroimaging, rehabilitation and telemedicine and on the management of functional disorders. There is no standardized approach to these issues that are often addressed differently by treating physicians and institutions.

The objective of the **ALPE-ADRIA Congress** is to define a common diagnostic and therapeutic approach to these conditions, sharing knowledge, developing protocols and establishing new collaborations among neurologists who manage these patients.



## THURSDAY, NOVEMBER 9, 2023

- 13:45 **Registration**
- 14:30 **Introduction to the Congress**  
*M. Tinazzi* (Verona, Italy), *A. Antonini* (Padua, Italy), *P. Manganotti* (Trieste, Italy)

**SESSION 1** **Update on diagnosis and treatment of alpha-synucleinopathy**

Chairs: *A. Berardelli* (Rome, Italy), *W. Poewe* (Innsbruck, Austria)

- 15:00 **Genetics of Parkinson's disease**  
*E.M. Valente* (Pavia, Italy)
- 15:30 **Alpha-synucleinopathies: clinical phenotypes**  
*P. Barone* (Salerno, Italy)
- 16:00 **New treatments**  
*W. Poewe* (Innsbruck, Austria)
- 16.30 **Discussion**

**SESSION 2** **Rehabilitation and digital telemedicine in Parkinson's disease**

Chairs: *A. Nicoletti* (Catania, Italy), *V. Tomantschger* (Görschach, Austria)

- 17:00 **Physical exercise in Parkinson's disease**  
*V. Tomantschger* (Görschach, Austria)
- 17:30 **Rehabilitation of gait and posture in Parkinson's disease**  
*M. Gandolfi* (Verona, Italy)
- 18:00 **Digital telemedicine**  
*A. Pilotto* (Brescia, Italy)
- 18:30 **Discussion**

19:00 **Welcome Cocktail**

## FRIDAY, NOVEMBER 10, 2023

**SESSION 3** **Motor and non motor symptoms in Parkinson's disease: how to recognize, how to treat**

Chairs: *M. Valente* (Udine, Italy), *G. Fabbrini* (Rome, Italy)

- 09:00 **Motor symptoms**  
*E. Ruzicka* (Prague, Czech Republic)
- 09:30 **Non motor symptoms**  
*M. Skorvanek* (Košice, Slovak Republic)
- 10:00 **Sleep**  
*E. Antelmi* (Verona, Italy)
- 10.30 **Discussion**
- 10.45 **Coffee Break**

**SESSION 4****Advanced treatment in movement disorders**

Chairs: *M. Zappia* (Catania, Italy), *V. Vuletić* (Rijeka, Croatia)

- 11.00 **DBS in movement disorders**  
*V. Vuletic* (Rijeka, Croatia)
- 11.30 **Infusion therapy**  
*M. Trost* (Ljubljana, Slovenia)
- 12.00 **Apomorphine**  
*Z. Pirtošek* (Ljubljana, Slovenia)
- 12.30 **MRgFUs**  
*E. Moro* (Grenoble, France)
- 13.00 **Discussion**

13.15 **Lunch**

**14:30-17:00****POSTER SESSION**

Chairs: *E. Belgrado* (Udine, Italy), *M. Catalan* (Trieste, Italy)

**Gait signature in patients with atypical parkinsonian syndromes**

*C. Raccagni, V. Sidoroff, N. Roth, I. Teckenburg, N. Hergenroeder-Lenzer, P. Bachmann, A. Ibrahim, H. Gassner, J. Winkler, D. Benninger, S. Buechner, B. Eskofier, K. Seppi, K. Aminian, J. Klucken, G. Wenning*

**The Global Parkinson's Genetics Program (GP2): worldwide Parkinson disease research**

*M. Avenali, L.M. Lange, S.Y. Lim, A.H. Tan, Z.H. Fang, I.J. Keller Sarmiento, K.R. Kumar, M. Ellis, J. Junker, A. Illarionova, H. Madoev, C. Galandra, P. Heutink, J. Solle, C. Wegel, M. Nalls, C. Blauwendraat, A. Singleton, K. Lohmann, N. Mencacci, C. Klein, E.M. Valente, The Global Parkinson's Genetics Program (GP)*

**Stress in Parkinson's disease: a prospective cohort study**

*E. Papić, V. Rački, M. Hero, V. Vuletić*

**Transauricular vagus stimulation improves subthalamic beta power and gait in Parkinson's disease**

*G. Anzini, L. Saltarocchi, R. Ricciuti, F. Capone, H. Tan, F. Torrecillos, J. Lanzone, V. Di Lazzaro, M. Marano*

**Levodopa induced myoclonus: a case report**

*E. Belgrado, Y. Tereshko, C. Lettieri, G. Valiante, S. Flumignan, M. Valente*

**Botulinum toxin administration in parkinsonian patients with lateral trunk flexion suggesting early Pisa Syndrome**

*V. Cenacchi, T.M.I. Lombardo, G. Bellavita, M. Catalan, V. Tommasini, M. Liccari, G. Mazzon, L. Antonutti, P. Manganotti*

**Acute hemichorea and stroke, management and treatment in 2 case reports**

*G. Prandin, I. Scali, L. Mancinelli, F. Palacino, E. Vincis, P. Caruso, G. Furlanis, M. Naccarato, P. Manganotti*

**Exploring the efficacy of psychoanalytic psychotherapy in managing functional neurological disorders: a preliminary analysis of healthcare utilization patterns**

*Y. Radin, A. Clarici, M. Bulfon, P. Caruso, P. Manganotti*

**"I know what I used to do": Cognitive Multisensory Rehabilitation with motor imagery in patients with Parkinson's disease**

*G. Sgubin, M. Deodato, P. Manganotti*

**Assessment of the therapeutic adherence to safinamide treatment at the Movement Disorder Unit of Trieste**

*T.M.I. Lombardo, M. Catalan, M. Liccari, V. Tommasini, L. Antonutti, P. Manganotti*

**Early motor symptoms result in faster exitus in patients with sporadic Creutzfeldt-Jakob disease: a case report**

*G. Iania, G. Furlanis, A. Favero, A. Bosco, D. Stokelj, P. Manganotti*

**Iron deposition within the basal ganglia and thalamus in early drug-naïve Parkinson's disease patients with and without REM behavioral disorders**

*M. D'Anna, R. De Micco, N. Piramide, F. Di Nardo, M. Siciliano, G. Caiazza, G. Tedeschi, F. Esposito, A. Tessitore*

**Distinct striatal connectivity patterns in patients with Parkinson's disease with and without urinary symptoms**

*N. Piramide, R. De Micco, F. Di Nardo, M. Siciliano, G. Caiazza, G. Tedeschi, F. Esposito, A. Tessitore*

**Brain local metabolic correlates of visual hallucinations in idiopathic Parkinson's disease**

*M. Michelutti, M. Catalan, M. Liccari, M. Ajčević, A. Cucca, T.M.I. Lombardo, V. Cenacchi, S. Rangan, C. Crisafulli, F. Dore, P. Manganotti*

**Comparing essential and dystonic tremor: the TITAN study**

*C. Sorrentino, G. Lazzeri, C. Terranova, G. Paparella, A.F. Gigante, R. De Micco, L. Magistrelli, F. Di Biasio, F. Valentino, V. Moschella, A. Pilotto, M. Esposito, E. Olivola, M.C. Malaguti, R. Ceravolo, C. Dallochio, F. Spagnolo, A. Nicoletti, A. De Rosa, R. Di Giacomo, A. Padovani, M.C. Altavista, C. Pacchetti, R. Marchese, E. Contaldi, A. Tessitore, S. Misceo, M. Bologna, V. Rizzo, G. Franco, P. Barone, R. Erro*

**Characterization of handwriting tremor in elderly parkinsonian patients by means of kinematic and spectral parameters**

*A. Raffini, A. Accardo*

**The contribution of cerebral small vessel disease to clinical phenotype in Progressive Supranuclear Palsy**

*A.R. Avallone, M.F. Tepedino, F. Diana, F. Abate, M. Caterino, R. Erro, M.T. Pellecchia, P. Barone, M. Picillo*

**Diagnostic efficacy of whole-exome sequencing in dystonia patients: results from a single tertiary center**

*M. Hero, G. Rožmarić, V. Rački, E. Papić, B. Petek, B. Peterlin, V. Vuletić*

**Genetic testing of dystonia before deep brain stimulation: a case report**

*G. Rožmarić, M. Hero, V. Rački, E. Papić, V. Vuletić*

**Whole-exome Sequencing Study of Parkinson's disease in the Croatian Population**

*V. Rački, G. Bergant, M. Hero, E. Papić, G. Rožmarić, B. Peterlin, V. Vuletić*

**Quantitative gait biomarkers in patients with functional gait disorders: beyond gait speed**

*M. Gandolfi, C. Bonetto, G. Bonardi, F. Salaorni, A. Sandri, C. Geroin, Z. Menaspà, N. Smania, M. Fiorio, M. Tinazzi*

**Elderly onset of functional motor disorders: clinical correlates from the Italian Registry**

*C. Geroin, M. Petracca, S. Di Tella, E. Marcuzzo, R. Erro, S. Cuoco, R. Ceravolo, S. Mazzucchi, A. Pilotto, A. Padovani, L.M. Romito, R. Eleopra, M. Zappia, A. Nicoletti, C. Dallochio, C. Arbasino, F. Bono, V. Laterza, B. Demartini, O. Gambini, N. Modugno, E. Olivola, L. Bonanni, A. Albanese, G. Ferrazzano, A. Tessitore, L. Lopiano, G. Calandra Buonauro, F. Morgante, M. Esposito, A. Pisani, P. Manganotti, L. Tesolin, F. Teatini, S. Camozzi, T. Ercoli, F. Stocchi, M. Coletti Moja, G. Defazio, M. Tinazzi*

**Identification of stroke mimics in the emergency department: the experience of Trieste's Neurological Clinic**

*P. Caruso, Y. Radin, A. Clarici, M. Bulfon, T.M.I. Lombardo, S. Pavan, P. Manganotti*

**Digital telemedicine in functional motor disorders: preliminary data on the health outcomes from a randomized controlled trial**

*F. Schena, M. Gandolfi, A. Sandri, Z. Menaspà, F. Bombieri, C. Geroin, M. Tinazzi*

**Decreased brain volume may be associated with occurrence of peri-lead edema in Parkinson disease patients with deep brain stimulation***H. Chudy, M. Raguž, P. Marčinković, D. Orešković, M. Lakić, D. Dlaka, N. Katavić, V. Rački, V. Vuletić, D. Chudy***Pain in people with multiple system atrophy: preliminary results from a web-based survey***N. Campese, B. Caliò, F. Leys, L. Kaltenbach, G. Göbel, J. Wanschitz, A. Schlager, P. Bower, L. Kellerman, L. Zamarian, K. Bannister, R. Chaudhuri, A. Schrag, R. Granata, S. Kiechl, W. Poewe, K. Seppi, G. Wenning, A. Fanciulli***The use of opicapone for the treatment of motor fluctuations in Parkinson's disease: real-life experience of two Italian Movement Disorders Centers***M. Liccari, R. Bacchin, M. Catalan, M.C. Malaguti, L. Antonutti, B. Giometto, P. Manganotti***RT-QuIC for detection of pathological  $\alpha$ -synuclein in the olfactory mucosa and CSF of Parkinson's disease patients***V. Tommasini, M. Bongiani, M. Catalan, D. Perra, P. Polverino, C. Bertolotti, R. Baruca, G. Bellavita, L. Antonutti, G. Zanusso, P. Manganotti***Transcranial Pulse Stimulation in Parkinson's rest tremor: a pilot study***M. Liccari, P. Manganotti, T.M.I. Lombardo, V. Cenacchi, M. Catalan***17:00-19:00****ORAL COMMUNICATIONS SESSION**Chairs: *M. Carecchio* (Padua, Italy), *R. De Micco* (Naples, Italy)**GBA mutations as a predictive genetic factor of clinical outcome in patients with Parkinson disease underwent to deep brain stimulation: multicentric longitudinal study on a large Italian cohort***M. Avenali, R. Zangaglia, G. Cuconato, I. Palmieri, A. Albanese, C.A. Artusi, M. Bozzali, G. Calandra Buonaura, F. Cavallieri, R. Cilia, A. Cocco, P. Cortelli, R. Eleopra, G. Giannini, A. Imarisio, G. Imbalzano, C. Ledda, L. Lopiano, M.C. Malaguti, F. Mameli, P. Mitrotti, F. Spagnolo, C. Tassorelli, F. Valentino, F. Valzania, A. Di Fonzo, C. Pacchetti, E.M. Valente***Efficacy of levodopa-carbidopa intestinal gel on freezing of gait and gait features in Parkinson's disease: prospective study with objective outcome measures***G. Imbalzano, C.A. Artusi, C. Ledda, E. Montanaro, A. Romagnolo, L. Lopiano, M. Zibetti***Functional connectivity network shapes atrophy spreading in Parkinson's disease***S. Basaia, E. Sarasso, R. Balestrino, T. Stojkovic, I. Stankovic, A. Tomic, V. Markovic, F. Vignaroli, E. Stefanova, V.S. Kostic, F. Agosta, M. Filippi***Functional MRI and gait analysis in patients with idiopathic REM sleep behavior disorder***R. Balestrino, F. Agosta, E. Sarasso, A. Gardoni, S. Marelli, L. Zenere, A. Castelnovo, A. Tettamanti, L. Ferini-Strambi, M. Filippi***Long-term effect of Botulinum toxin in lateral trunk flexion associated with Parkinson's disease***C.A. Artusi, C. Ledda, E. Panero, F. Marchet, C. Geroin, M. Gandolfi, M. Tinazzi, L. Lopiano***AQP4 levels in CSF correlates with clinical severity in iNPH patients. A preliminary report***E. Belgrado, Y. Theresko, F. Tuniz, D. Piccolo, M. Fabris, A. Cifù, D. Bagatto, M. Valente***Changes of Brain-Derived Neurotrophic Factor (BDNF) levels after different exercise protocols: a systematic review of clinical studies in Parkinson's disease***A. Paterno, G. Polsinelli, B. Federico***MRgFUS motor effects in tremor-dominant Parkinson's disease beyond tremor: a single center experience***P. Sucapane, S. Ratti, G. Saporito, T. Russo, D. Cerone, C. Marini, F. Bruno, A. Catalucci, F. Pistoia*

### Using illusions to understand hallucinations: high order perceptual impairments underscore differences in performance on illusory figures in Parkinson's disease

A. Cucca, M. Catalan, C.V. Manara, M. Liccari, L. Antonutti, T.M.I. Lombardo, V. Cenacchi, V. Tommasini, S. Rangan, S. Mingolo, F. Dore, C. Crisafulli, M. Murgia, T. Agostini, P. Manganotti

### Utility of 123I-Metaiodobenzylguanidine myocardial scintigraphy in differentiating PD from MSA patients

M. Catalan, F. Dore, P. Polverino, C. Bertolotti, A. Sartori, L. Antonutti, A. Cucca, G. Furlanis, S. Capitano, P. Manganotti

### Cognitive-motor dual-tasking in early Parkinson's disease: an ERP study

M. Peskar, P. Manganotti, U. Marusic

### Long-term effects of 24-week telemedicine program in patients with functional motor disorders: a prospective cohort study

A. Sandri, M. Gandolfi, Z. Menaspà, F. Bombieri, V. Vandelli, M. Tinazzi

## SATURDAY, NOVEMBER 11, 2023

### SESSION 5 *Hyperkinetic disorders*

Chairs: P. Manganotti (Trieste, Italy), M. Tinazzi (Verona, Italy)

09.00

#### **Tremor**

R. Erro (Salerno, Italy)

09.30

#### **Dystonia/ataxia**

A. Tomic (Belgrade, Serbia)

10.00

#### **Functional neurological disorders**

T. Serranova (Prague, Czech Republic)

10.30

#### **Discussion**

10.45

#### **Coffee Break**

### SESSION 6 *Neuroimaging in movement disorders*

Chairs: A. Antonini (Padua, Italy), I. Rektorova (Brno, Czech Republic)

11.00

#### **Parkinson's Disease**

I. Rektorova (Brno, Czech Republic)

11.30

#### **Atypical parkinsonisms**

A. Fanciulli (Innsbruck, Austria)

12.00

#### **Dystonia**

F. Agosta (Milan, Italy)

12.30

#### **Functional movement disorders**

S. Aybek (Bern-Freiburg, Switzerland)

13.00

#### **Discussion**

## GENERAL INFORMATION

### CME Credits

The Meeting provides **nr. 11,2 credits** for Physicians (specialists in Neurology, Neurosurgery, Physical Medicine and Rehabilitation, Radiology, Geriatrics and Psychiatry), Psychologist and Physiotherapists. **Certification of credits is subject to verification of learning and participation in the entire training programme.**

### Registration fees

- € 50,00 (+VAT 22%) Under 35 MDS or LIMPE-DISMOV Members
- € 70,00 (+VAT 22%) Under 35 NOT Members
- € 150,00 (+VAT 22%) MDS or LIMPE-DISMOV Members
- € 200,00 (+VAT 22%) NOT Members

*The registration fee includes: participation at scientific sessions, materials, coffee breaks, lunch and welcome cocktail.*

*With the unrestricted grant of*

abbvie

Bial

Boston  
Scientific  
Advancing science for life™

Chiesi

ecupharma

EVER  
PHARMA

inomed

INSIGHTEC

LUSOFARMACO

MERZ

Zambon